These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28376212)

  • 1. Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
    Weller M; Roth P; Sahm F; Burghardt I; Schuknecht B; Rushing EJ; Regli L; Lindemann JP; von Deimling A
    J Natl Cancer Inst; 2017 Mar; 109(3):1-4. PubMed ID: 28376212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AKT1
    John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.
    Sahm F; Bissel J; Koelsche C; Schweizer L; Capper D; Reuss D; Böhmer K; Lass U; Göck T; Kalis K; Meyer J; Habel A; Brehmer S; Mittelbronn M; Jones DT; Schittenhelm J; Urbschat S; Ketter R; Heim S; Mawrin C; Hainfellner JA; Berghoff AS; Preusser M; Becker A; Herold-Mende C; Unterberg A; Hartmann C; Kickingereder P; Collins VP; Pfister SM; von Deimling A
    Acta Neuropathol; 2013 Nov; 126(5):757-62. PubMed ID: 24096618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
    Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
    J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
    J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Mutant AKT in Cancer.
    Cancer Discov; 2016 Jan; 6(1):OF7. PubMed ID: 26577299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visceral and bone metastases of a WHO grade 2 meningioma: A case report and review of the literature.
    Paix A; Waissi W; Antoni D; Adeduntan R; Noël G
    Cancer Radiother; 2017 Feb; 21(1):55-59. PubMed ID: 28237610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
    Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
    Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature.
    Mordechai O; Postovsky S; Vlodavsky E; Eran A; Constantini S; Dotan E; Cagnano E; Weyl-Ben-Arush M
    Pediatr Hematol Oncol; 2015 Apr; 32(3):207-11. PubMed ID: 25116269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical management of meningiomas.
    Chukwueke UN; Wen PY
    Handb Clin Neurol; 2020; 170():291-302. PubMed ID: 32586501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
    Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
    Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus effectively blocks pulmonary metastases from meningioma.
    Bertolini F; Pecchi A; Stefani A; Fontana A; Rossi G
    Neuro Oncol; 2015 Sep; 17(9):1301-2. PubMed ID: 26293327
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway.
    Johnson MD; O'Connell MJ; Pilcher W; Reeder JE
    J Neurosurg; 2010 May; 112(5):934-9. PubMed ID: 19698046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A gain of function mutation in AKT1 increases hexokinase 2 and diminishes oxidative stress in meningioma.
    Singh S; Lathoria K; Umdor SB; Singh J; Suri V; Sen E
    Cytokine; 2024 Apr; 176():156535. PubMed ID: 38325141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic AKT1 mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis.
    Keppler-Noreuil KM; Baker EH; Sapp JC; Lindhurst MJ; Biesecker LG
    Am J Med Genet A; 2016 Oct; 170(10):2605-10. PubMed ID: 27550858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
    Johnson MD; O'Connell MJ; Walter K
    BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.